Hub : Traits :

Medication: Amlodipine

57 significantly associated models · 24 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	10435170	12156236	2	2	4.4e-09	8.5e-21	7.6e-13	41	CLCN6 RP4-635E18.7
2	1	27013133	28406173	1	1	9.0e-08	1.1e-05	5.4e-01	98	CD164L2
3	1	112312154	113907148	5	2	1.8e-12	9.4e-15	1.1e-07	53	CTTNBP2NL RHOC
4	2	26291565	27689899	1	1	1.3e-07	6.2e-12	8.8e-07	49	SLC35F6
5	3	26720690	28211713	1	1	1.8e-07	5.3e-07	2.3e-03	63	SLC4A7
6	11	1213806	2640824	2	2	4.4e-12	4.1e-12	1.5e-01	96	LSP1 TNNT3
7	11	99859184	101559718	2	1	1.4e-09	4.8e-09	2.2e-01	96	TMEM133
8	12	121146219	122706844	2	1	1.6e-07	8.8e-08	1.0e+00	100	RNF34
9	15	90730363	92135418	1	1	2.3e-10	6.1e-08	6.0e-01	99	FES
10	17	7269373	7784295	1	1	7.0e-08	5.7e-07	3.9e-03	67	SHBG
11	17	25990033	27387415	1	1	2.6e-07	5.9e-06	1.1e-04	27	TMEM199
12	17	55903829	57920532	5	1	7.1e-09	2.9e-08	2.9e-02	84	SKA2

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.43	1	0	0.0	0.00	1.0e+00	FES
Bipolar Disorder or Schizophrenia	2.67	2	1	2.2	0.00	1.0e+00	CLCN6 FES
Neuroticism (Nagel 2018)	0.99	1	0	0.0	0.00	1.0e+00	FES
Schizophrenia (2018)	2.54	1	1	2.2	0.00	1.0e+00	FES
Worry (Nagel 2018)	0.79	1	0	0.0	0.00	1.0e+00	SKA2
Irritable Bowel Disease (IBD)	1.93	1	0	0.0	0.00	1.0e+00	LSP1
Ulcerative Colitis (UC)	1.80	1	0	0.0	0.00	1.0e+00	LSP1
Reaction Time	1.93	1	0	0.0	0.00	1.0e+00	SKA2
Breast Cancer	8.42	4	2	4.4	0.73	2.7e-01	FES LSP1 SLC4A7 TNNT3
Fasting Glucose	1.45	1	0	0.0	0.00	1.0e+00	RNF34
LDL Cholesterol	1.51	1	0	0.0	0.00	1.0e+00	TMEM199
Schizophrenia (2014)	2.15	1	1	2.2	0.00	1.0e+00	FES
Type 2 Diabetes (T2D) (2012)	2.98	1	0	0.0	0.00	1.0e+00	SKA2
Ulcerative Colitis	2.52	1	0	0.0	0.00	1.0e+00	LSP1
Blood Eosinophil Count	0.67	2	0	0.0	0.00	1.0e+00	CD164L2 CLCN6
Blood Platelet Count	1.17	5	2	4.4	-0.83	8.3e-02	CTTNBP2NL LSP1 RHOC SLC4A7 TMEM199
Blood Red Count	1.11	6	1	2.2	-0.35	5.0e-01	CLCN6 FES LSP1 RHOC SHBG SLC35F6
Blood White Count	1.20	5	1	2.2	-0.22	7.2e-01	FES LSP1 SLC35F6 SLC4A7 TMEM133
Heel T-Score	1.93	6	4	8.9	-0.57	2.4e-01	CTTNBP2NL RHOC RP4-635E18.7 SLC4A7 TMEM133 TMEM199
BMI	0.99	3	0	0.0	0.00	1.0e+00	CLCN6 RNF34 SLC35F6
Height	1.47	11	4	8.9	-0.65	2.9e-02	FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199 TNNT3
Waist Hip Ratio (WHR)	1.22	2	0	0.0	0.00	1.0e+00	SHBG TNNT3
Systolic Blood Pressure	26.67	15	12	26.7	0.86	3.3e-05	CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TMEM199 TNNT3
Smoking Status	0.85	1	0	0.0	0.00	1.0e+00	FES
Allergy or Eczema	2.25	3	0	0.0	0.00	1.0e+00	CLCN6 FES RNF34
Cardiovascular Disease	19.93	14	13	28.9	0.94	7.4e-07	CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TNNT3
Respiratory disease	1.78	2	0	0.0	0.00	1.0e+00	FES SHBG
Type 2 Diabetes (T2D) (2018)	1.31	1	0	0.0	0.00	1.0e+00	SKA2
Lung FEV1/FVC ratio	1.29	2	2	4.4	0.00	1.0e+00	CTTNBP2NL TMEM133
Lung FVC	0.91	2	0	0.0	0.00	1.0e+00	CLCN6 CTTNBP2NL
Chronotype (morning person)	1.35	1	0	0.0	0.00	1.0e+00	SKA2
Hair Pigment	0.24	2	1	2.2	0.00	1.0e+00	FES TMEM133
Tanning	0.29	2	0	0.0	0.00	1.0e+00	CLCN6 TMEM133
Hand grip strength (left)	1.53	3	0	0.0	0.00	1.0e+00	FES RHOC SHBG
Number of treatments/medications taken	4.34	3	1	2.2	0.00	1.0e+00	FES RHOC TMEM133
Sensitivity / hurt feelings	2.20	2	1	2.2	0.00	1.0e+00	FES SKA2
Systolic blood pressure, automated reading	18.98	10	7	15.6	0.90	4.6e-04	CLCN6 FES LSP1 RHOC RP4-635E18.7 SHBG SLC4A7 TMEM133 TMEM199 TNNT3
Angina	3.93	2	1	2.2	0.00	1.0e+00	FES TMEM133
Impedance of leg (right)	1.99	7	1	2.2	0.13	7.8e-01	CD164L2 FES RHOC SHBG SLC35F6 SLC4A7 TMEM133
Leg fat-free mass (left)	1.70	6	0	0.0	-0.54	2.6e-01	FES RP4-635E18.7 SHBG SLC35F6 TMEM133 TMEM199
Trunk fat percentage	1.57	3	0	0.0	0.00	1.0e+00	RNF34 SHBG TNNT3
Hand grip strength (right)	1.86	2	0	0.0	0.00	1.0e+00	RHOC SHBG
Age when periods started (menarche)	1.79	2	0	0.0	0.00	1.0e+00	LSP1 TNNT3
Heel bone mineral density (BMD) T-score, automated (left)	1.78	2	0	0.0	0.00	1.0e+00	TMEM133 TMEM199
High blood pressure	23.58	14	13	28.9	0.94	4.1e-07	CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TNNT3
Hayfever, allergic rhinitis or eczema	1.91	3	0	0.0	0.00	1.0e+00	CLCN6 FES RNF34
Medication: Atenolol	8.71	5	1	2.2	0.96	9.5e-03	CLCN6 FES RHOC TMEM133 TNNT3
Sitting height	1.28	5	1	2.2	0.44	4.6e-01	CD164L2 FES SHBG SLC35F6 SLC4A7
High blood pressure (mother)	10.92	8	1	2.2	0.91	1.7e-03	CLCN6 FES LSP1 RHOC RNF34 SLC4A7 TMEM133 TNNT3
Body mass index (BMI)	0.81	2	0	0.0	0.00	1.0e+00	RNF34 SKA2
Impedance of leg (left)	2.02	6	1	2.2	0.20	7.1e-01	CD164L2 FES RHOC SHBG SLC35F6 TMEM133
Leg predicted mass (left)	1.69	6	0	0.0	-0.54	2.6e-01	FES RP4-635E18.7 SHBG SLC35F6 TMEM133 TMEM199
Trunk fat mass	1.21	1	0	0.0	0.00	1.0e+00	RNF34
Waist circumference	1.00	1	0	0.0	0.00	1.0e+00	SKA2
Number of incorrect matches in round	1.50	1	0	0.0	0.00	1.0e+00	FES
Alcohol usually taken with meals	1.93	1	0	0.0	0.00	1.0e+00	FES
Had other major operations	2.47	1	0	0.0	0.00	1.0e+00	SHBG
Forced vital capacity (FVC)	1.42	2	1	2.2	0.00	1.0e+00	RHOC TMEM133
Heel bone mineral density (BMD) T-score, automated (right)	1.71	2	0	0.0	0.00	1.0e+00	TMEM133 TMEM199
Heart attack	3.38	2	1	2.2	0.00	1.0e+00	CD164L2 FES
Allergy	2.02	3	0	0.0	0.00	1.0e+00	CLCN6 FES RNF34
Medication: Ramipril	6.78	4	1	2.2	0.99	1.2e-02	FES LSP1 TMEM133 TNNT3
Medication: Simvastatin	4.36	2	1	2.2	0.00	1.0e+00	FES TMEM133
Illnesses of siblings	5.15	5	1	2.2	0.12	8.5e-01	CLCN6 FES RHOC SLC4A7 TMEM133
Weight	1.26	3	0	0.0	0.00	1.0e+00	RP4-635E18.7 SKA2 SLC35F6
Impedance of arm (right)	1.88	4	1	2.2	-0.48	5.2e-01	LSP1 SHBG SLC4A7 TNNT3
Arm fat percentage (right)	1.34	1	0	0.0	0.00	1.0e+00	RNF34
Trunk fat-free mass	2.02	5	2	4.4	-0.27	6.6e-01	SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Hip circumference	1.28	2	1	2.2	0.00	1.0e+00	CLCN6 SKA2
Father's age at death	2.48	1	1	2.2	0.00	1.0e+00	FES
Hair/balding pattern: Pattern 3	1.04	1	0	0.0	0.00	1.0e+00	CLCN6
Forced expiratory volume in 1-second (FEV1)	1.28	2	0	0.0	0.00	1.0e+00	RHOC TMEM133
Asthma	1.70	2	0	0.0	0.00	1.0e+00	CLCN6 FES
Medication: Cholesterol lowering	4.73	3	2	4.4	0.00	1.0e+00	CLCN6 FES TMEM133
Illnesses of mother	6.75	2	1	2.2	0.00	1.0e+00	FES TMEM133
Forced expiratory volume in 1-second (FEV1), Best measure	1.00	2	0	0.0	0.00	1.0e+00	RHOC TMEM133
Pulse wave Arterial Stiffness index	2.50	2	0	0.0	0.00	1.0e+00	CLCN6 FES
Impedance of arm (left)	1.99	4	1	2.2	-0.46	5.4e-01	LSP1 SHBG SLC4A7 TNNT3
Arm fat mass (right)	1.01	1	0	0.0	0.00	1.0e+00	RNF34
Trunk predicted mass	2.01	5	2	4.4	-0.27	6.6e-01	SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Standing height	1.25	5	2	4.4	-0.66	2.2e-01	LSP1 RHOC RP4-635E18.7 SHBG SLC35F6
Breastfed as a baby	1.59	1	0	0.0	0.00	1.0e+00	FES
Hair/balding pattern: Pattern 4	1.35	1	0	0.0	0.00	1.0e+00	FES
Birth weight of first child	4.91	2	2	4.4	0.00	1.0e+00	CLCN6 FES
Headache pain in last month	2.00	2	0	0.0	0.00	1.0e+00	FES SKA2
Medication for cholesterol, blood pressure or diabetes	11.80	7	3	6.7	-0.05	9.1e-01	CLCN6 CTTNBP2NL FES LSP1 RHOC SLC4A7 TMEM133
Birth weight	3.01	1	1	2.2	0.00	1.0e+00	FES
High blood pressure (siblings)	9.22	6	2	4.4	0.98	8.2e-04	CLCN6 FES RHOC SLC4A7 TMEM133 TNNT3
Forced vital capacity (FVC), Best measure	1.11	1	0	0.0	0.00	1.0e+00	RHOC
Body fat percentage	1.50	3	0	0.0	0.00	1.0e+00	CLCN6 RNF34 SHBG
Leg fat percentage (right)	1.30	3	0	0.0	0.00	1.0e+00	CLCN6 RNF34 SKA2
Arm fat-free mass (right)	1.70	5	1	2.2	-0.25	6.9e-01	SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Pulse wave peak to peak time	2.56	2	0	0.0	0.00	1.0e+00	CLCN6 FES
Medication: Blood pressure	17.86	11	7	15.6	0.94	1.9e-05	CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SLC4A7 TMEM133 TNNT3
Angina (self-reported)	3.91	2	1	2.2	0.00	1.0e+00	FES TMEM133
Medication: Allopurinol	1.03	1	0	0.0	0.00	1.0e+00	SHBG
Mean time to correctly identify matches	2.35	3	0	0.0	0.00	1.0e+00	FES SKA2 SLC4A7
Heart disease (mother)	3.39	2	0	0.0	0.00	1.0e+00	FES SLC4A7
Whole body fat mass	1.08	1	0	0.0	0.00	1.0e+00	RNF34
Leg fat mass (right)	0.94	1	0	0.0	0.00	1.0e+00	RNF34
Arm predicted mass (right)	1.77	4	1	2.2	-0.12	8.8e-01	SHBG SLC35F6 SLC4A7 TMEM199
Pulse rate, automated reading	1.47	2	0	0.0	0.00	1.0e+00	SHBG SLC4A7
Comparative height size at age 10	0.82	2	1	2.2	0.00	1.0e+00	FES RP4-635E18.7
Suffer from 'nerves'	1.12	1	0	0.0	0.00	1.0e+00	SKA2
Medication: Aspirin	4.84	2	1	2.2	0.00	1.0e+00	FES RNF34
Hypertension (Self-reported)	23.68	14	13	28.9	0.94	5.5e-07	CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TNNT3
Gastro-oesophageal reflux (gord) / gastric reflux (Self-reported)	1.52	1	0	0.0	0.00	1.0e+00	RNF34
Illnesses of father: Heart disease	3.80	1	1	2.2	0.00	1.0e+00	FES
Whole body fat-free mass	1.89	6	2	4.4	-0.31	5.5e-01	FES SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Leg fat-free mass (right)	1.81	7	1	2.2	-0.32	4.8e-01	FES RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Arm fat percentage (left)	1.42	2	0	0.0	0.00	1.0e+00	RNF34 SHBG
Handedness (chirality/laterality): Left-handed	1.43	1	0	0.0	0.00	1.0e+00	FES
Friendships satisfaction	1.44	1	0	0.0	0.00	1.0e+00	SLC35F6
Medication for cholesterol	10.23	10	3	6.7	-0.99	2.7e-08	CD164L2 CLCN6 FES LSP1 RHOC RNF34 RP4-635E18.7 SLC35F6 TMEM133 TNNT3
Mineral and other dietary supplements	1.25	1	0	0.0	0.00	1.0e+00	FES
Breast cancer (self-reported)	2.74	1	1	2.2	0.00	1.0e+00	SLC4A7
Asthma (self-reported)	1.69	1	0	0.0	0.00	1.0e+00	FES
Medication: Aspirin	5.43	2	1	2.2	0.00	1.0e+00	FES RNF34
Illnesses of father: None of the above (group 1)	4.71	1	1	2.2	0.00	1.0e+00	FES
Forced expiratory volume in 1-second (FEV1), predicted percentage	0.90	1	0	0.0	0.00	1.0e+00	TMEM133
Whole body water mass	1.90	7	2	4.4	-0.34	4.5e-01	FES RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Leg predicted mass (right)	1.83	7	1	2.2	-0.33	4.7e-01	FES RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TMEM199
Arm fat mass (left)	1.02	1	0	0.0	0.00	1.0e+00	RNF34
Number of self-reported non-cancer illnesses	4.52	3	0	0.0	0.00	1.0e+00	CLCN6 RNF34 TMEM133
Mother's age at death	2.88	1	0	0.0	0.00	1.0e+00	CLCN6
Medication: Blood pressure	19.96	13	7	15.6	0.97	7.4e-08	CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TNNT3
High cholesterol (Self-reported)	4.02	4	1	2.2	0.20	8.0e-01	CD164L2 CLCN6 FES TMEM133
Medication: Bendroflumethiazide	15.83	12	7	15.6	0.98	2.0e-08	CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RP4-635E18.7 SHBG SLC35F6 SLC4A7 TMEM133 TNNT3
Medication: Lisinopril	5.66	4	0	0.0	-0.88	1.2e-01	FES LSP1 RHOC TMEM133
Illnesses of father: High blood pressure	8.70	5	1	2.2	0.71	1.8e-01	CLCN6 FES LSP1 SLC4A7 TMEM133
Ever smoked	1.37	2	0	0.0	0.00	1.0e+00	FES RNF34
Basal metabolic rate	1.71	5	1	2.2	-0.50	3.9e-01	RP4-635E18.7 SHBG SLC35F6 TMEM133 TMEM199
Leg fat percentage (left)	1.22	2	0	0.0	0.00	1.0e+00	CLCN6 RNF34
Arm fat-free mass (left)	1.78	4	1	2.2	-0.14	8.6e-01	SHBG SLC35F6 SLC4A7 TMEM199
Risk taking	1.46	1	0	0.0	0.00	1.0e+00	FES
Age started oral contraceptive pill	1.36	1	0	0.0	0.00	1.0e+00	FES
Diastolic blood pressure, automated reading	13.28	7	6	13.3	0.87	1.1e-02	CLCN6 FES LSP1 RHOC RP4-635E18.7 TMEM133 TNNT3
Myopia	1.19	1	0	0.0	0.00	1.0e+00	RHOC
Vascular/heart problems diagnosed by doctor	22.35	14	11	24.4	-0.93	1.7e-06	CD164L2 CLCN6 CTTNBP2NL FES LSP1 RHOC RNF34 RP4-635E18.7 SHBG SKA2 SLC35F6 SLC4A7 TMEM133 TNNT3
Cholesterol lowering medication	3.45	1	0	0.0	0.00	1.0e+00	RNF34
Heart attack/myocardial infarction (self-reported)	3.28	2	1	2.2	0.00	1.0e+00	CD164L2 FES
Heart disease (siblings)	2.01	1	0	0.0	0.00	1.0e+00	FES
Impedance of whole body	1.92	6	1	2.2	-0.21	6.9e-01	LSP1 SHBG SLC35F6 SLC4A7 TMEM133 TNNT3
Leg fat mass (left)	0.88	1	0	0.0	0.00	1.0e+00	RNF34
Arm predicted mass (left)	1.82	4	1	2.2	-0.14	8.6e-01	SHBG SLC35F6 SLC4A7 TMEM199

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	1	0.029	1.5
GTEx	Adipose Visceral Omentum	0	0.000	1.5
GTEx	Adrenal Gland	1	0.069	1.5
GTEx	Artery Aorta	3	0.101	1.5
GTEx	Artery Coronary	0	0.000	1.5
GTEx	Artery Tibial	4	0.106	1.5
GTEx	Brain Caudate basal ganglia	0	0.000	1.4
GTEx	Brain Cerebellar Hemisphere	0	0.000	1.3
GTEx	Brain Cerebellum	0	0.000	1.4
GTEx	Brain Cortex	0	0.000	1.4
GTEx	Brain Frontal Cortex BA9	0	0.000	1.4
GTEx	Brain Hippocampus	0	0.000	1.5
GTEx	Brain Hypothalamus	0	0.000	1.4
GTEx	Brain Nucleus accumbens basal ganglia	0	0.000	1.4
GTEx	Brain Putamen basal ganglia	0	0.000	1.3
GTEx	Breast Mammary Tissue	0	0.000	1.5
GTEx	Breast Mammary Tissue (Male)	1	0.084	1.4
GTEx	Breast Mammary Tissue (Female)	0	0.000	1.5
GTEx	Cells EBV-transformed lymphocytes	0	0.000	1.4
GTEx	Cells Transformed fibroblasts	3	0.071	1.4
GTEx	Colon Sigmoid	0	0.000	1.5
GTEx	Colon Transverse	0	0.000	1.5
GTEx	Esophagus Gastroesophageal Junction	0	0.000	1.5
GTEx	Esophagus Mucosa	0	0.000	1.4
GTEx	Esophagus Muscularis	0	0.000	1.5
GTEx	Heart Atrial Appendage	0	0.000	1.4
GTEx	Heart Left Ventricle	0	0.000	1.4
GTEx	Liver	0	0.000	1.3
GTEx	Lung	2	0.070	1.5
GTEx	Muscle Skeletal	2	0.069	1.4
GTEx	Nerve Tibial	3	0.069	1.4
GTEx	Ovary	0	0.000	1.5
GTEx	Pancreas	0	0.000	1.5
GTEx	Pituitary	0	0.000	1.4
GTEx	Prostate	0	0.000	1.5
GTEx	Skin Not Sun Exposed Suprapubic	1	0.041	1.5
GTEx	Skin Sun Exposed Lower leg	0	0.000	1.4
GTEx	Small Intestine Terminal Ileum	0	0.000	1.4
GTEx	Spleen	0	0.000	1.5
GTEx	Stomach	1	0.069	1.5
GTEx	Testis	1	0.032	1.4
GTEx	Thyroid	0	0.000	1.4
GTEx	Uterus	0	0.000	1.4
GTEx	Vagina	0	0.000	1.5
GTEx	Whole Blood	1	0.050	1.4
METSIM	Adipose	2	0.043	1.4
NTR	Blood	0	0.000	1.4
ROSMAP	Brain Pre-frontal Cortex	2	0.046	1.5
YFS	Blood	1	0.022	1.3
CommonMind	Brain Pre-frontal Cortex	2	0.037	1.4
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	2	0.121	1.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	2	0.045	1.4
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	2	0.182	1.4
The Cancer Genome Atlas	Colon Adenocarcinoma	0	0.000	1.4
The Cancer Genome Atlas	Esophageal Carcinoma	0	0.000	1.3
The Cancer Genome Atlas	Glioblastoma Multiforme	0	0.000	1.4
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	4	0.147	1.4
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	3	0.073	1.4
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	1	0.049	1.4
The Cancer Genome Atlas	Brain Lower Grade Glioma	1	0.023	1.4
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	1	0.090	1.4
The Cancer Genome Atlas	Lung Adenocarcinoma	2	0.068	1.4
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	2	0.080	1.4
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	1	0.063	1.4
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	0	0.000	1.4
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	0	0.000	1.3
The Cancer Genome Atlas	Prostate Adenocarcinoma	1	0.022	1.4
The Cancer Genome Atlas	Rectum Adenocarcinoma	0	0.000	1.4
The Cancer Genome Atlas	Soft Tissue Sarcoma	0	0.000	1.4
The Cancer Genome Atlas	Skin Cutaneous Melanoma	0	0.000	1.3
The Cancer Genome Atlas	Stomach Adenocarcinoma	1	0.059	1.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	0	0.000	1.3
The Cancer Genome Atlas	Thyroid Carcinoma	3	0.058	1.3
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	0	0.000	1.6